Forest Laboratories generics, pharmaceuticals news
Activist investor Carl Icahn announced plans to nominate a slate of directors for election to Forest's board for the second straight year. Eric Ende, who was a member of Icahn's failed slate last year, is the only nominee disclosed. Ende has represented Icahn on multiple biotech boards, including Genzyme Corp., which is now part of Sanofi (Euronext:SAN; NYSE:SNY, Paris, France). Forest said in a statement it is "puzzled and disappointed that Mr. Icahn's first chosen method of engagement since last year is the threat of yet another proxy contest." All of the company's 10 directors are up for reelection at the 2012 annual meeting, which has yet to be scheduled. Last year's meeting was held on Aug. 18. Icahn holds a 9.92% stake in Forest. ...